Guardion Health Sciences (GHSI) Gets a Buy from Maxim Group

Maxim Group analyst Anthony Vendetti maintained a Buy rating on Guardion Health Sciences (GHSIResearch Report) yesterday and set a price target of $0.60. The company’s shares opened today at $0.16.

Vendetti covers the Healthcare sector, focusing on stocks such as Aethlon Medical, ReShape Lifesciences, and Guardion Health Sciences. According to TipRanks, Vendetti has an average return of 3.1% and a 36.77% success rate on recommended stocks.

Currently, the analyst consensus on Guardion Health Sciences is a Moderate Buy with an average price target of $0.68.

See Insiders’ Hot Stocks on TipRanks >>

Based on Guardion Health Sciences’ latest earnings release for the quarter ending March 31, the company reported a quarterly revenue of $2.38 million and a GAAP net loss of $2.62 million. In comparison, last year the company earned a revenue of $233.3 thousand and had a GAAP net loss of $2.67 million

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Guardion Health Sciences, Inc. provides health care services. It offers, Lumega-Z a medical food formulated to replenish and restore the macular protective pigment. The firm also develops medical devices that measures macular pigment density. The company was founded by Michael Favish in 2009 and is headquartered in San Diego, CA.

Read More on GHSI:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More